Methods of using TICAM-1, an adapter protein that binds...

Details Methods of using TICAM-1, an adapter protein that binds... Methods of using TICAM-1, an adapter protein that binds...

2009-03-31

2011-10-04

Bunner, Bridget E (Department: 1647)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S070100, C435S070300, C435S455000, C435S069100, C435S007210, C530S351000, C536S023500

Reexamination Certificate

active

08029778

ABSTRACT:
A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1.

REFERENCES:
patent: 7227007 (2007-06-01), Matsuda et al.
patent: 2003/0143540 (2003-07-01), Matsuda et al.
patent: 2003/0170719 (2003-09-01), Matsuda et al.
patent: 2007/0105198 (2007-05-01), Matsuda et al.
patent: 1354950 (2003-10-01), None
patent: 00/78954 (2000-12-01), None
patent: 02/053737 (2002-07-01), None
patent: 2004/044201 (2004-05-01), None
Rubanyi, biol. Aspects Med. 2001, vol. 22, pp. 113-142.
Juengst, British Medical Journal, 2003, vol. 326, pp. 1410-1411.
Matsumoto. Biochemical and Biophysical Research Communication, 2002, vol. 293, pp. 1364-1369.
Akazawa et al, Cancer Research, 2004, vol. 64, pp. 757-764.
Jablonska et al, The Journal of Clinical Investigation, 2010, vol. 120, No. 4, pp. 1151-1163.
Dunn et al, Nature Reviews, 2006, vol. 6, pp. 836-848.
Anderson “Human gene therapy” Nature 392:25-30 (1998).
Crystal “Transfer of genes to humans: Early lessons and obstacles to success” Science 270:404-410 (1995).
Kaufman et al. “Transgenic analysis of a 100-kb human β-globin cluster-containing DNA fragment propagated as a bacterial artificial chromosome” Blood 94:3178-3184 (1999).
Wang et al. “Rapid analysis of gene expression (RAGE) facilitates universal expression profiling” Nucl. Acid Res. 27:4609-4618 (1999).
Office Action in related U.S. Appl. No. 12/385,128, mailed Jan. 12, 2010.
Akira et al. “Murine TIR domain-containing adaptor inducing interferon-beta protein” GENESEQ Accession No. AD033467 from WO 2004/044201 (Aug. 2004).
Alexopoulou et al. “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3” Nature 413:732-738 (2001).
Fitzgerald et al. “Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction” Nature 413:78-83 (2001).
Horng et al. “TIRAP: An adapter molecule in the Toll signaling pathway” Nature Immunol. 2:835-841 (2001).
Imler et al. “Toll signaling: The TIReless quest for specificity” Nature Immunol. 4:105-106 (Feb. 2003).
Kawai et al. “Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes” J. Immunol. 167:5887-5894 (2001).
Lal et al. “TICAM1 protein (fragment)” UNIPROT Accession No. Q8JZVO from WO 00/78954 (Oct. 2002).
Lazar et al. “Transforming growth factor α: Mutation of aspartic acid 47 and leucine 48 results in different biological activities” Mol. Cell. Biol. 8:1247-1252 (1988).
Matsuda et al. “Human NF-κB activating protein” GENESEQ Accession No. ABP61500 from WO 02/053737 (Sep. 2002).
Matsumoto et al. “Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling” Biochem. Biophys. Res. Comm. 293:364-1369 (May 2002).
Oshiumi et al. “TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction” Nature Immunol. 4:161-167 (Feb. 2003).
Oshiumi et al. “TICAM-1” UNIPROT Accession No. Q80UF7 from the above document (Jun. 2003).
Wells “Additivity of mutational effects in proteins” Biochemistry 29:8509-8517 (1990).
Yamamoto et al. “Cutting edge: A novel Toll/IL receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling” J. Immunol. 169:6668-6672 (Dec. 2002).
Yamamoto et al. “TIR domain containing adaptor inducing interferon-beta (TICAM-1) putative NFκB activating protein” UNIPROT Accession No. Q8IUC6 from the above document (Mar. 2003).
International Search Report for PCT/JP2003/014854, one page, dated Jan. 13, 2004.
Int'l Preliminary Report on Patentability for PCT/JP2003/014854, five pages, dated Jul. 7, 2004.
Supplementary search report for EP 03774108, six pages, dated Apr. 28, 2006.
Su et al. “A gene atlas of the mouse and human protein-encoding transcriptomes” Proc. Natl. Acad. Sci. USA nol. 101, No. 16, pp. 6062-6067 (Apr. 2004).
Office Action in related Canadian Appln. No. 2,507,716, three pages, mailed Apr. 30, 2009.

Affiliated with

Also associated with

Rating

Methods of using TICAM-1, an adapter protein that binds... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using TICAM-1, an adapter protein that binds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using TICAM-1, an adapter protein that binds... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4283212